Tirzepatide: Compound Overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first molecule in its class. It is a 39-amino acid peptide with a molecular weight of 4813.45 Da, incorporating Aib substitutions at positions 2 and 13 for DPP-IV resistance and a C20 fatty diacid moiety at lysine-20 that enables albumin binding and extends the half-life to approximately 5 days (120 hours). This guide provides detailed reconstitution procedures, concentration calculations, dosing tables, and storage protocols specific to tirzepatide research applications.
As a larger peptide with dual-receptor activity, tirzepatide requires careful handling to maintain structural integrity and biological activity. The reconstitution, dosing, and storage practices described here are based on the properties of the specific molecule and published research protocols.
Reconstitution Volumes and Concentrations
The choice of reconstitution volume determines the working concentration. Select a volume that provides convenient dosing increments for your protocol while maximizing the number of usable doses per vial.
5 mg vial reconstitution options: Adding 1 mL of bacteriostatic water yields 5 mg/mL (5000 mcg/mL). This high concentration is suitable when larger doses are needed in smaller volumes. Adding 2 mL yields 2.5 mg/mL (2500 mcg/mL), a popular choice providing convenient dosing increments with standard U-100 insulin syringes. Adding 2.5 mL yields 2 mg/mL (2000 mcg/mL), further simplifying dose calculations for certain protocols.
10 mg vial reconstitution options: Adding 2 mL yields 5 mg/mL (5000 mcg/mL). Adding 4 mL yields 2.5 mg/mL (2500 mcg/mL). Adding 5 mL yields 2 mg/mL (2000 mcg/mL). The 10 mg vial offers more total doses per reconstitution event, reducing the frequency of reconstitution and the associated contamination risk.
30 mg vial reconstitution options: Adding 3 mL yields 10 mg/mL (10000 mcg/mL). Adding 6 mL yields 5 mg/mL (5000 mcg/mL). Adding 12 mL yields 2.5 mg/mL (2500 mcg/mL). The 30 mg vial is economical for sustained research programs with established protocols. Higher concentration options (10 mg/mL) require precise syringe technique due to the small volumes per dose.
Step-by-Step Reconstitution Procedure
Step 1 — Workspace Preparation. Assemble all materials on a clean, flat work surface: tirzepatide vial, bacteriostatic water vial, appropriately sized sterile syringe (1 mL or 3 mL), sterile needles, 70% isopropanol alcohol swabs, nitrile gloves, and a permanent marker for labeling. If available, work in a laminar flow hood. Put on nitrile gloves before handling any materials.
Step 2 — Temperature Equilibration. Remove the tirzepatide vial from -20°C freezer storage and place it on the work surface. Allow 15–20 minutes for the vial to reach room temperature. Do not attempt to accelerate warming by placing the vial in warm water or using body heat, as rapid temperature changes can cause condensation inside the vial (introducing moisture to the lyophilized powder) and may promote degradation of the peptide. During this equilibration period, you can prepare your syringe, verify your concentration calculations, and prepare your vial label.
Step 3 — Aseptic Solvent Addition. Swab the stopper of both the tirzepatide vial and the bacteriostatic water vial with alcohol pads. Allow 30 seconds for the alcohol to evaporate completely. Draw the calculated volume of bacteriostatic water into the syringe, ensuring no air bubbles are present (tap the syringe gently and push out any bubbles before removing from the BAC water vial). Insert the needle through the tirzepatide vial stopper and direct the stream of BAC water down the inside wall of the vial. Do not spray directly onto the lyophilized cake. Add the solvent slowly and steadily to avoid foaming and mechanical stress on the peptide.
Step 4 — Dissolution. Allow the vial to sit undisturbed on a flat surface for 3–5 minutes. Tirzepatide typically dissolves readily, but larger vials (10 mg and 30 mg) may require slightly longer passive dissolution time. If undissolved material remains after 5 minutes, gently roll the vial between your palms for 30–60 seconds, or tilt it slowly back and forth. Never shake the vial. Vigorous agitation creates air bubbles that promote oxidation of susceptible residues and can cause the peptide to adsorb to bubble surfaces, reducing effective concentration.
Step 5 — Visual Inspection. The reconstituted solution should be clear, colorless, and free of visible particles or cloudiness. Hold the vial against a dark background and a light source to check for turbidity or particulate matter. If the solution appears cloudy, allow additional time for dissolution. Persistent cloudiness after 15 minutes of gentle mixing may indicate a problem with the solvent, pH, or peptide integrity. Do not use turbid solutions for quantitative research.
Step 6 — Labeling and Documentation. Using a permanent marker or printed label, record the following on the vial: peptide name (tirzepatide), concentration (e.g., 2.5 mg/mL), reconstitution date, expiration date (30 days from reconstitution), and your initials. Record the batch number, reconstitution details, and storage location in your laboratory notebook.
Dosing Reference Tables
At 2.5 mg/mL (5 mg in 2 mL): 0.5 mg = 20 units (0.20 mL). 1.0 mg = 40 units (0.40 mL). 2.5 mg = 100 units (1.00 mL). These increments align well with published dose escalation protocols.
At 5 mg/mL (10 mg in 2 mL): 1.0 mg = 20 units (0.20 mL). 2.5 mg = 50 units (0.50 mL). 5.0 mg = 100 units (1.00 mL). This higher concentration is preferred when minimizing injection volume is important.
At 10 mg/mL (30 mg in 3 mL): 2.5 mg = 25 units (0.25 mL). 5.0 mg = 50 units (0.50 mL). 10.0 mg = 100 units (1.00 mL). Maximum concentration for protocols requiring high doses.
Storage and Stability
Store the reconstituted solution at 2–8°C in a dedicated laboratory refrigerator. Place the vial upright in the back of the refrigerator where temperature is most stable. Do not store on door shelves. With bacteriostatic water, reconstituted tirzepatide is stable for up to 30 days under proper refrigeration. Do not freeze reconstituted solutions — ice crystal formation causes mechanical damage and promotes aggregation. If you need longer-term storage, prepare single-use aliquots in sterile microcentrifuge tubes and freeze at -20°C; thaw each aliquot only once.
Tirzepatide-Specific Research Considerations
Tirzepatide's half-life of approximately 5 days supports once-weekly subcutaneous dosing in research protocols. Steady-state plasma concentrations are reached after 4–5 weekly administrations. Published clinical trial protocols (SURPASS and SURMOUNT programs) employed dose escalation schedules starting at lower doses (typically 2.5 mg weekly for 4 weeks) with stepwise increases at 4-week intervals. This gradual escalation improves gastrointestinal tolerability, as nausea and reduced appetite are the most commonly reported effects in published studies.
The dual GIP/GLP-1 receptor agonism of tirzepatide creates a more complex pharmacological profile than selective GLP-1 agonists like semaglutide. When comparing results to selective GLP-1 agonist data, the GIP component's effects on adipose tissue metabolism, lipid handling, and central appetite regulation must be considered. Tirzepatide demonstrates biased agonism at GLP-1R (favoring cAMP over beta-arrestin) that differs from semaglutide's signaling profile, which may contribute to observed differences in efficacy and tolerability.
Common Mistakes to Avoid
Do not shake the vial during or after reconstitution. Do not use non-sterile water sources. Do not store reconstituted solution at room temperature. Do not refreeze thawed aliquots. Do not use reconstituted solution beyond 30 days. Do not mix tirzepatide with other peptides in the same vial without specific validation. Do not use a vial if the solution has become cloudy, discolored, or contains visible particles during storage.
Disclaimer
For research purposes only. Not for human consumption.